StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Kisqali by Quarter

Kisqali — New Prescription (NBRx) Market Share in Early Breast Cancer (eBC) in Germany (%)

Novartis Kisqali: 80.0% in Q3 2026, up 3.0 pts from a year earlier.

Latest, Q3 2026
80.0%
Period ended Sep 30, 2026
Change on a year earlier
+3.0 pts
77.0% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“| • Clear eBC leadership in DE (80%), UK (77%)2,”

Source: Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗

Reported in Quarterly Investor Presentations.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Novartis Kisqali (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rx-kisqali-de-ebc-nbrx-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.